MM-252: Aberrant Plasma Cells in the Apheresis Product as a Prognostic Factor for Minimal Residual Disease Negativity After Transplant in Newly Diagnosed Myeloma Patients — Panagiotis Malandrakis (2020) | RDL Network
MM-252: Aberrant Plasma Cells in the Apheresis Product as a Prognostic Factor for Minimal Residual Disease Negativity After Transplant in Newly Diagnosed Myeloma Patients
Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva, Shaji Kumar, Meletios A Dimopoulos, Thierry Façon, María‐Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michèle Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh,
Michèle Cavo, Jesús F. San Miguel, Saad Z. Usmani, Katja Weisel, Meletios A Dimopoulos, Hervé Avet‐Loiseau, Bruno Paiva, Nizar J. Bahlis, Torben Plesner, Vânia Hungria, Philippe Moreau, María‐Victoria Mateos, Aurore Perrot, Shinsuke Iida, Thierry Façon, Shaji Kumar, Niels W.C.J. van de Donk, Pieter Sonneveld, Andrew Spencer, Maria Krevvata, Christoph Heuck, Jianping Wang, Jon Ukropec,
Discussion(0)
No comments yet. Be the first to comment.